Gene · 64761
Papers1,639
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,639
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer. | Cancer Metab | 2026 | 41857765 | PubTator, text mining | PubMed |
| SLFN11 Enhances PARPi Sensitivity in Ovarian Cancer via Ubiquitin-Mediated Stabilization. | DNA Cell Biol | 2026 | 41830441 | PubTator, text mining | PubMed |
| Cross-tissue integrative transcriptomic and multimodal analyses suggest shared immune signatures linking lupus nephritis and cutaneous lupus erythematosus. | Front Immunol | 2026 | 41816342 | PubTator, text mining | PubMed |
| cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells. | Front Oncol | 2026 | 41809821 | PubTator, text mining | PubMed |
| PARP-2 catalytic activity drives replication-ICL repair in an allele-specific manner during germline development. | PLoS Genet | 2026 | 41785248 | PubTator, text mining | PubMed |
| HPF1 regulates the formation of FUS-dependent compartments by PARP1 and PARP2 activation on damaged DNA. | Nucleic Acids Res | 2026 | 41773021 | PubTator, text mining | PubMed |
| Molecular Design with Artificial Intelligence: Progress and Perspectives for Small Molecules. | Chem Rev | 2026 | 41764645 | PubTator, text mining | PubMed |
| Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas. | Nat Commun | 2026 | 41760625 | PubTator, text mining | PubMed |
| Yeast as a Platform to Dissect Poly(ADP-Ribose) Polymerase Function from Magnaporthe oryzae and Evaluate PARP Inhibitors. | Int J Mol Sci | 2026 | 41752036 | PubTator, text mining | PubMed |
| Synergistic Antitumor Activity of Curcumin and the PARP1 Inhibitor PJ34 in Platinum-Sensitive and Resistant Ovarian Cancer Cells. | Cancers (Basel) | 2026 | 41749873 | PubTator, text mining | PubMed |
| Tankyrases and Their Binding Proteins: Origins of Their Roles in Diverse Cellular Pathways. | Cells | 2026 | 41744791 | PubTator, text mining | PubMed |
| Advancing inducible gene-inactivation systems to explore synthetic lethality. | NAR Cancer | 2026 | 41736896 | PubTator, text mining | PubMed |
| Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. | PeerJ | 2026 | 41736752 | PubTator, text mining | PubMed |
| Advances in solid handling for continuous flow synthesis of specialty chemicals and pharmaceuticals. | Commun Chem | 2026 | 41730978 | PubTator, text mining | PubMed |
| Regulation of Activity of DNA Polymerases β and λ by XRCC1, PARP1, and PARP2 Proteins. | Biochemistry (Mosc) | 2026 | 41702736 | PubTator, text mining | PubMed |
| Palladium-catalysed synthesis of small-molecule epigenetic inhibitors as anticancer therapeutics. | J Enzyme Inhib Med Chem | 2026 | 41693699 | PubTator, text mining | PubMed |
| Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors. | J Enzyme Inhib Med Chem | 2026 | 41693691 | PubTator, text mining | PubMed |
| Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. | Proc Natl Acad Sci U S A | 2026 | 41591905 | PubTator, text mining | PubMed |
| Automodification of N-terminal serine residues facilitates PARP2 release from DNA. | FEBS J | 2026 | 41578964 | PubTator, text mining | PubMed |
| Integrative Bioinformatics and Machine Learning Identify Novel Diagnostic Biomarkers and Molecular Mechanisms in Sjögren's Syndrome. | Int J Genomics | 2026 | 41551935 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64761/papers?page=2